Please assess the completion status of the following clinical trial:

Trial Title: Empagliflozin for the Treatment of Postprandial Hypoglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients after bariatric surgery (i.e. sleeve gastrectomy, Roux-en-Y gastric bypass, omega- loop bypass, biliopancreatic diversion) with documented hypoglycemia, i. e. \< 3.0 mmol/l and at least 5 hypoglycemic episodes per week despite dietary modification~* For women with child-bearing potential, willingness to use contraceptive measures adequate to prevent pregnancy during the study~* Informed Consent as documented by signature~Exclusion Criteria:~* Any type of diabetes mellitus according to ADA criteria~* Intolerance to the study drug~* Signs of current infection~* Use of any drug therapy for postbariatric hypoglycemia apart from acarbose (all remaining drugs have to be discontinued four half-life times before screening phase)~* Neutropenia (leukocyte count \< 1.5 × 109/L or absolute neutrophil count (ANC) \< 0.5 × 109/L)~* Anemia (hemoglobin \< 11 g/dL for males, \< 10 g/dL for females)~* Clinically significant kidney or liver disease (creatinine \> 1.5 mg/dL, AST/ALT \> 2 × ULN, alkaline phosphatase \> 2 × ULN, or total bilirubin \[tBili\] \> 1.5 × ULN)~* Uncontrolled congestive heart failure~* Uncontrolled malignant disease~* Currently pregnant or breastfeeding~* Known or suspected non-compliance, drug or alcohol abuse~* Meeting the criteria for vulnerability (e.g. participants incapable of judgment or participants under tutelage)~* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.~* Participation in another clinical trial using investigational drugs in the last 30 days or planned participation in the next 60 days~* Previous enrolment into the current study,~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: EXPERIMENTAL): Standard dose of empagliflozin (Jardiance®; Boehringer Ingelheim GmbH), i. e. 10 mg. Empagliflozin is an orally available inhibitor of SGLT2 and approved for the treatment of type 2 diabetes mellitus and will be given per os once daily in the morning for 28 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo provided by Boehringer Ingelheim Switzerland. Per os once daily in the morning for 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).